Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Use of biologic agents in rheumatoid arthritis: introduction.

Silman AJ.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv3-4. doi: 10.1093/rheumatology/ker239. No abstract available.

PMID:
21859703
2.

Biologics in rheumatoid arthritis--recommendations for Swiss practice.

Dudler J, Möller B, Michel BA, Villiger PM.

Swiss Med Wkly. 2011 May 10;141:w13189. doi: 10.4414/smw.2011.13189.

3.

Comparative overview of safety of the biologics in rheumatoid arthritis.

Khraishi M.

J Rheumatol Suppl. 2009 Jun;82:25-32. doi: 10.3899/jrheum.090128. Review.

PMID:
19509327
4.

Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.

Strand V.

Z Rheumatol. 1998 Feb;57(1):41-5. Review. No abstract available.

PMID:
9566107
5.

Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans.

Barton P.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv32-iv38. doi: 10.1093/rheumatology/ker244.

PMID:
21859704
6.

IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.

Tanaka Y, Martin Mola E.

Ann Rheum Dis. 2014 Sep;73(9):1595-7. doi: 10.1136/annrheumdis-2013-205002. No abstract available.

PMID:
24833786
7.

The British Society for Rheumatology Biologics Register: 6 years on.

Hyrich KL, Watson KD, Isenberg DA, Symmons DP; BSR Biologics Register..

Rheumatology (Oxford). 2008 Oct;47(10):1441-3. doi: 10.1093/rheumatology/ken242. No abstract available.

PMID:
18596052
8.

Rheumatoid arthritis: Evidence-based rather than habit-based treatment options.

Yazici Y.

Nat Rev Rheumatol. 2012 May 29;8(7):374-6. doi: 10.1038/nrrheum.2012.79. No abstract available.

PMID:
22641135
9.

'Treat to target' for rheumatoid arthritis in 2014--time tested triple therapy or logical biologics?

Mok MY, Danda D.

Int J Rheum Dis. 2014 Jan;17(1):1-3. doi: 10.1111/1756-185X.12313. No abstract available.

PMID:
24472259
10.

[Rheumatoid arthritis: early aggressive therapy including biologicals -- pro].

Rubbert-Roth A.

Dtsch Med Wochenschr. 2005 Aug 19;130(33):1900. German. No abstract available.

PMID:
16118736
11.

[Position on choice of agents among TNF inhibitors].

Manger B; Kommission Pharmakotherapie der DGRh..

Z Rheumatol. 2005 Mar;64(2):88-9. German. No abstract available.

PMID:
15793672
12.

Joint approach.

Palmer K.

Minn Med. 2009 Sep;92(9):22-5. No abstract available.

PMID:
19877473
13.

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ.

Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv2-14. Review. No abstract available.

14.

[Focusing on the use of biologics in rheumatoid arthritis].

Devauchelle-Pensec V, Guellec D.

Rev Prat. 2015 May;65(5):687-8. French. No abstract available.

PMID:
26165113
15.

Therapeutic targets for rheumatoid arthritis.

Keystone EC, Haraoui B.

J Rheumatol Suppl. 2009 Jun;82:1. doi: 10.3899/jrheum.090123. No abstract available.

PMID:
19509323
16.

Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?

Kavanaugh A.

Nat Clin Pract Rheumatol. 2006 Jul;2(7):346-7. Review. No abstract available.

PMID:
16932716
17.

Adherence to biologic DMARD therapies in rheumatoid arthritis.

Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L.

Expert Opin Biol Ther. 2010 Sep;10(9):1367-78. doi: 10.1517/14712598.2010.510508. Review.

PMID:
20681888
18.

Biologic therapy for rheumatoid arthritis.

Klippel JH.

N Engl J Med. 2000 Nov 30;343(22):1640-1. No abstract available. Erratum in: N Engl J Med 2001 Jan 4;344(1):76.

PMID:
11096174
19.

Rheumatoid arthritis in 2003: where are we now with treatment?

Weinblatt ME.

Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii94-6. Review. No abstract available.

20.

Supplemental Content

Support Center